

May 24, 2023

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943

**Stock Symbol: JBCHEPHARM** 

Dear Sir,

Sub: Disclosure of related party transactions under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed please find disclosure of related party transactions for the second half of the financial year 2022-23.

We request you to take the above on record.

Thanking you,

Yours faithfully, For J.B. Chemicals & Pharmaceuticals Limited

Sandeep Phadnis
Vice President-Secretarial
& Company Secretary



www.jbpharma.com

Prabhadevi, Mumbai – 400025, T+91 22 24395200/5500 secretarial@jbpharma.com

· · · · · · · · · · · · · · · · · · ·													(Rs. in lakhs)						
										Additional disclosure of related party transactions - applicable only in case the related party									
	Details of the party (listed entity	sted entity Value of the Value of						In case any financial											
	/subsidiary) entering into the				related party	transaction			indebtedne	ss is incu	rred to								
	transaction				transaction as	during the			make or g	ve loans.	inter-	Details of the loans, inter-corporate deposits, advances							
		,			approved by	reporting			corporate des			or investments							
					the audit	period HY				stments	varices or	'							
			- 1 11 6.1	Type of related party	committee/	Mar!22			Nature of				D						
S. No			Relationship of the	transaction	Board					Cost		Nature				Purpose for			
			counterparty with the listed		Board				indebtedness			(loan/			Secured/	which the			
	Name	Name	entity or its subsidiary				Opening	Closing	(loan/		Ten	advance/	Interest	Ten	unsecur	funds will be			
	Name	Name					Balance	balance	issuance of		ure	inter-	Rate (%)	ure	ed	utilised by			
									debt/ any			corporate			eu	the ultimate			
									other etc.)			deposit/				recipient of			
	J. B. Chemicals &	OOO Unique Pharmaceutical	Subsidiary	Sale of goods	5,500.00	2,603.62	4,267.82	2,317.64											
1	Pharmaceuticals Limited	Laboratories	,	· ·															
	J. B. Chemicals &	000 Unique Pharmaceutical	Subsidiary	Marketing Service Fees	3,000.00	237.57	-580.72	-											
2	Pharmaceuticals Limited	Laboratories	,	paid	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,														
	J. B. Chemicals &	000 Unique Pharmaceutical	Subsidiary	Compensation Cost- ESOP	126.00	38.55	-	192.82											
3	Pharmaceuticals Limited	Laboratories	,	recovery															
			Subsidiary	Guarantee Commission	18.50	12.50	-	2.09											
4	J. B. Chemicals &	OOO Unique Pharmaceutical	Subsidialy	recovered	10.30	12.30		2.03		1						1			
-	Pharmaceuticals Limited	Laboratories		recovered															
	J. B. Chemicals &	OOO Unique Pharmaceutical	Subsidiary	Recovery of expenses	161.00	108.59	-	13.65		l -	1		<del>                                     </del>	-					
5	Pharmaceuticals Limited	Laboratories	Substitiety	necovery of expenses	101.00	106.39	1	13.05		l		1		l					
1			Chaidiaa.	Commention Cost 5500	122.01	CC 12	142.00	210.01		<b>-</b>	-	-	<del>                                     </del>	-		<del>                                     </del>			
6	J. B. Chemicals &	Unique Pharmaceutical	Subsidiary	Compensation Cost- ESOP	132.81	66.12	143.90	210.04		l									
	Pharmaceuticals Limited	Laboratories FZE		recovery															
7	J. B. Chemicals &	Unique Pharmaceutical	Subsidiary	Compensation Cost- ESOP	28.00	20.49	-	20.49											
	Pharmaceuticals Limited	Laboratories FZE		recovery															
8	J. B. Chemicals &	Unique Pharmaceutical	Subsidiary	Marketing Support Fees	105.00	104.17	-	-105.29											
	Pharmaceuticals Limited	Laboratories FZE																	
q	J. B. Chemicals &	Biotech Laboratories (Pty.)	Subsidiary	Sale of goods	11,300.00	5,312.83	2,245.42	1,512.10											
,	Pharmaceuticals Limited	limited																	
10	J. B. Chemicals &	Biotech Laboratories (Pty.)	Subsidiary	Technical Service fee	247.00	136.17	-	131.97											
10	Pharmaceuticals Limited	limited		received															
11	J. B. Chemicals &	Biotech Laboratories (Pty.)	Subsidiary	Reimbursement of	25.00	16.76	-	16.80											
11	Pharmaceuticals Limited	limited		expenses															
	I. B. Chemicals &		KMP	*Remuneration (including	654.50	331.84	-	-											
12	J. B. Chemicals & Pharmaceuticals Limited	Mr. Nikhil Chopra		retiral benefits)															
	Pharmaceuticals Limited																		
			KMP	*Remuneration (including	262.20	131.07	-	-											
13	J. B. Chemicals &	Mr. Lakshay Kataria		retiral benefits)												1			
	Pharmaceuticals Limited	,														1			
			KMP	*Remuneration (including	65.92	32.94	-	-											
14	J. B. Chemicals &	Mr. Sandeep Phadnis		retiral benefits)															
	Pharmaceuticals Limited			,												1			
			KMP of Subsidiary	*Remuneration (including	502.10	329.02	-	-											
15	OOO Unique Pharmaceutical	Mr. Sandeep Nasa	, , , , , , , , , , , , , , , , , , , ,	retiral benefits)												1			
13	Laboratories	Wil. Salideep Wasa		remar benefits)															
			KMP of Subsidiary	*Remuneration (including	91.00	91.00	-	-								<b>—</b>			
16	Unique Pharmaceutical	Mr. Sandeep Nasa	KIVIF OI SUUSIUIAI'Y		51.00	51.00													
10	Laboratories FZE	wii. Sailueep NaSa		retiral benefits)						l		1		l					
$\vdash$			CEO of Subsidiars	*Romunoration (including	388.00	191.53	-	-		-				-		<b>—</b>			
	Biotech Laboratories (Pty.)	M. St. Carlotte	CEO of Subsidiary	*Remuneration (including	388.00	191.53	-	1		l		1		l					
17	Limited	Mr. Stewart Barker		retiral benefits)						l		1		l					
-			Foods on the head	***************************************			1	-	-	-	-	-	-	-		+			
1	Unique Pharmaceutical		Employee of subsidiary	*Remuneration (including	5.00	2.77	-	-		l		1		l					
18	Laboratories FZE	Mr. Stewart Barker		retiral benefits)															
										<u> </u>									
	J. B. Chemicals &		KMP	^Share option exercise		186.25	-	-											
19	Pharmaceuticals Limited	Mr. Nikhil Chopra		price received						l		1		l					
																<b></b>			
20	J. B. Chemicals &	Mr. Lakshay Kataria	KMP	Share option exercise		53.76	-	-											
20	Pharmaceuticals Limited	caksilay katalla		price received															
21	J. B. Chemicals &	Mr. Sandeep Phadnis	KMP	Share option exercise		11.04	-	-											
2.1	Pharmaceuticals Limited	wii. Saliueep Filauliis		price received															
22	J. B. Chemicals &	Mr. Nikhil Chopra	KMP	\$ Share based perquisites		303.86	-	-											
22	Pharmaceuticals Limited	Wit. Mikilii Cilopia		value															
23	J. B. Chemicals &	Mr. Lakshay Kataria	KMP	Share based perquisites		32.93	-	-					1	1					
23	Pharmaceuticals Limited	IVII. Laksiiay kalafia		value						L	<u> </u>	L							
24	J. B. Chemicals &	Mr. Candona Bhadain	KMP	Share based perquisites		7.63	-	-											
24	Pharmaceuticals Limited	Mr. Sandeep Phadnis		value						1									
			*	*				•			•								

25	Biotech Laboratories (Pty.) Limited	Mr. Shadrack Mapetla	Chairman of Board of subsidiary	Sitting fees	4.10	1.46	-	-				
26	J. B. Chemicals & Pharmaceuticals Limited	ipharma (Pty.) Ltd., South AFrica	Spouse of subsidiary's CEO is director and minority shareholder	Sale of goods	1,620.00	709.09	671.58	631.79				
27	Biotech Laboratories (Pty.) Limited	ipharma (Pty.) Ltd., South AFrica	Spouse of subsidiary's CEO is director and minority shareholder	Purchase of goods	3,300.00	1,886.93	-153.51	-556.43				
28	J. B. Chemicals & Pharmaceuticals Limited	Tau Investment Holdings Pte. Ltd.	Holding Company	#Dividend	3,547.25	3,547.25	-	-				
Total						16507.74						

Note:

\*Remuneration (excluding ESOP cost).

A During the Financial Year 2022-23, total share option exercise price received pursuant to exercise of ESOPs under the JBCPL ESOP Scheme 2021 was Rs. 320.35 Lakhs

5 During the Financial Year 2022-23, total share based perquisite value on exercise of ESOPs under the JBCPL ESOP Scheme 2021 was Rs. 501.25 Lakhs

#During the Financial Year 2022-23, total dividend paid to Tau Investment Holdings Pte. Ltd. was Rs. 6885.83 Lakhs

Negative figures represent the outstanding payables.